Pharmaceutical

SK pharmteco and Rznomics sign MoU to develop gene therapies

SK pharmteco has entered an MoU with South Korea-based Rznomics for the development and manufacture of RNA-based gene therapies.

Aug 7, 2024 - 04:00
SK pharmteco and Rznomics sign MoU to develop gene therapies
SK pharmteco has entered an MoU with South Korea-based Rznomics for the development and manufacture of RNA-based gene therapies.
Read the original article

Tags:

Previous Article

How SaaS platforms are breaking the mold for clinical trials

Next Article

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks

Top 20 biopharma kick off 9.6% market cap surge in Q1 2...

Apr 27, 2024

Carmot’s chance of beating the odds in the biotech market just ended

Carmot’s chance of beating the odds in the biotech mark...

Dec 5, 2023

STAT+: FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases

STAT+: FDA cites Fresenius Kabi for contamination probl...

Oct 4, 2023